Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420265 | 0.93 | GAA (0.40) | TP53POLBHTTMCL1P2RY1 | |
| SCHEMBL6420125 | 0.92 | MCL1 (0.43) | POLBMCL1P2RY1MAPTKMT2A | |
| SCHEMBL6419684 | 0.92 | TP53 (0.37) | TP53POLBHTTMCL1P2RY1 | |
| SCHEMBL6421823 | 0.90 | MCL1 (0.41) | TP53POLBHTTMCL1P2RY1 | |
| SCHEMBL6419648 | 0.86 | MCL1 (0.41) | POLBMCL1P2RY1MAPTKMT2A | |
| SCHEMBL6420083 | 0.85 | MCL1 (0.43) | MCL1P2RY1MAPTKMT2A | |
| SCHEMBL6420214 | 0.85 | MCL1 (0.41) | POLBHTTMCL1P2RY1SMN1; SMN2 | |
| SCHEMBL6421449 | 0.83 | MCL1 (0.42) | MCL1P2RY1MAPTKMT2A | |
| SCHEMBL6647217 | 0.82 | MCL1 (0.41) | MCL1P2RY1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6420042 | 0.82 | P2RY1 (0.49) | POLBP2RY1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | TP53 766/4885POLB 4822/4885HTT 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.